Allegheny Health Network Partners with The START Center to Enhance Cancer Trial Accessibility

Allegheny Health Network and The START Center Collaborate for Cancer Research

In a significant move to improve patient access to cutting-edge cancer therapies, Allegheny Health Network (AHN) has announced a strategic collaboration with The START Center for Cancer Research. This partnership is set to establish a new early-phase clinical trial site within the AHN Cancer Center at Allegheny General Hospital, located in Pittsburgh.

Addressing a Growing Need

Western Pennsylvania has long faced challenges in accessing early-phase oncology clinical trials. With around 89,000 new cancer cases diagnosed each year across the state, many patients historically needed to travel far from their communities to participate in these crucial trials. This new collaboration aims to bridge that gap, enabling local patients easier access to innovative treatments and research opportunities closer to home.

The START Center, known globally for its network of dedicated early-phase oncology trial sites, will integrate its expertise into AHN's system of care. This unique setup will allow clinical trials to be woven into standard patient care processes, effectively reducing barriers and making participation more accessible to those in need.

Experts Come Together

Nick Slack, Chairman and CEO of START, emphasized the importance of this alliance, stating, "The future of oncology research depends on bringing clinical trials closer to where patients already receive care." He highlighted that AHN possesses not only the infrastructure of a leading health system but also a strong culture of innovation, both of which position it perfectly for this type of collaboration.

Similarly, Dr. David Bartlett, chair of the AHN Cancer Center, noted, "We are committed to ensuring our patients access the most innovative cancer treatments available today and those still on the horizon," highlighting the commitment both organizations share in providing the latest advancements in oncology care.

Benefits for Patients

By embedding a START site directly within the AHN Cancer Center, patients will have opportunities to participate in clinical trials as part of their ongoing care. This integration will enhance patient convenience and bring advanced research into the local healthcare environment.

The patient experience stands to be markedly improved as they will no longer need to leave their familiar healthcare settings to engage in groundbreaking treatment options. Instead, they can partake in innovative research programs without the challenges of travel and logistics that have previously posed obstacles.

AHN operates a comprehensive cancer care network, boasting over 200 specialized physicians and 500 oncology professionals. With 24 associated oncology clinics and over 20,000 new patients served each year, the AHN Cancer Center serves as a flagship hub for advanced cancer diagnostics and treatments in the region. The collaboration with START not only expands AHN's reach but also deepens the pool of resources available to patients in pursuit of cutting-edge cancer therapies.

START's Global Network

The START Center is recognized as the world’s largest network for early-phase clinical trial sites, with over 40 Principal Investigators at 16 different locations in the United States and Europe. With nearly 1,000 active studies and numerous collaborations with leading pharmaceutical companies, START facilitates access to a vast array of early-phase cancer trials that can lead to groundbreaking therapies for patients worldwide.

The newly established site at AHN will be fully integrated into this global network allowing immediate access to an extensive portfolio of industry-sponsored early-phase cancer trials from the outset.

Conclusion

In conclusion, the collaboration between Allegheny Health Network and The START Center for Cancer Research is a promising step forward in enhancing cancer care accessibility in Western Pennsylvania. By marrying innovative research with community-centered healthcare, this partnership is set not only to improve patient outcomes but also strengthen the future of oncology research in the region.